Exploration of the importance of the P2-P3 -NHCO-moiety in a potent Di- or tripeptide inhibitor of calpain I:: Insights into the development of nonpeptidic inhibitors of calpain I

被引:12
作者
Chatterjee, S
Iqbal, M
Mallya, S
Senadhi, SE
O'Kane, TM
McKenna, BA
Bozyczko-Coyne, D
Kauer, JC
Siman, R
Mallamo, JP
机构
[1] Cephalon Inc, Dept Chem, W Chester, PA 19380 USA
[2] Cephalon Inc, Dept Biochem, W Chester, PA 19380 USA
关键词
stroke; calpain I; peptidomimetic; ketomethylene; carbamethylene;
D O I
10.1016/S0968-0896(98)00009-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Calpain I, an intracellular cysteine protease, has been implicated in the neurodegeneration following an episode of cerebral ischemia. In this paper, we report on a series of peptidomimetic ketomethylene and carbamethylene inhibitors of recombinant human calpain I (rh calpain I). Our study reveals that the -NHCO-moiety (possible hydrogen-bonding site) at the P-2-P-3 region of a potent tripeptide or a dipeptide inhibitor of calpain I is not a strict requirement for enzyme recognition. Compounds 7d ((R)-2-isobutyl-4-oxo-4-(9-xanthenyl)but acid ((S)-1-formyl-3-methyl)butyl amide), 31 ((R)-2-isobutyl-4-(2-sulfonylnaphthyl)butyric acid ((S)1-formyl-3-methyl)butyl amide) and 34 ((R)-2-isobutyl-4-(2-sulfoxylnaphthyl)butyric acid ((S)-1-formyl-3-methyl)butyl amide) which exhibited good activity in the enzyme assay, also inhibited calpain I in a human cell line. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:509 / 522
页数:14
相关论文
共 25 条
[1]   INACTIVATION OF CALPAIN BY PEPTIDYL FLUOROMETHYL KETONES [J].
ANGLIKER, H ;
ANAGLI, J ;
SHAW, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (02) :216-220
[2]  
Barinaga M, 1996, SCIENCE, V272, P664
[3]  
BRENNAN MB, 1996, CHEM ENG NEWS 0513, P41
[4]   Xanthene derived potent nonpeptidic inhibitors of recombinant human calpain I [J].
Chaterjee, S ;
Iqbal, M ;
Kauer, JC ;
Mallamo, JP ;
Senadhi, S ;
Mallya, S ;
BozyczkoCoyne, D ;
Siman, R .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (13) :1619-1622
[5]   Potent fluoromethyl ketone inhibitors of recombinant human calpain I+ [J].
Chatterjee, S ;
Josef, K ;
Wells, G ;
Iqbal, M ;
Bihovsky, R ;
Mallamo, JP ;
Ator, MA ;
BozyczkoCoyne, D ;
Mallya, S ;
Senadhi, S ;
Siman, R .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (11) :1237-1240
[6]   Nonpeptidic inhibitors of recombinant human calpain I [J].
Chatterjee, S ;
Senadhi, S ;
BozyczkoCoyne, D ;
Siman, R ;
Mallamo, JP .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (03) :287-290
[7]   THE DESIGN OF PEPTIDYLDIAZOMETHANE INHIBITORS TO DISTINGUISH BETWEEN THE CYSTEINE PROTEINASES CALPAIN-II, CATHEPSIN-L AND CATHEPSIN-B [J].
CRAWFORD, C ;
MASON, RW ;
WIKSTROM, P ;
SHAW, E .
BIOCHEMICAL JOURNAL, 1988, 253 (03) :751-758
[8]   CHEMISTRY OF OXAZIRIDINES .9. SYNTHESIS OF 2-SULFONYLOXAZIRIDINES AND 2-SULFAMYLOXAZIRIDINES USING POTASSIUM PEROXYMONOSULFATE (OXONE) [J].
DAVIS, FA ;
CHATTOPADHYAY, S ;
TOWSON, JC ;
LAL, S ;
REDDY, T .
JOURNAL OF ORGANIC CHEMISTRY, 1988, 53 (09) :2087-2089
[9]   ASPARTYL ALPHA-((1-PHENYL-3-(TRIFLUOROMETHYL)PYRAZOL-5-YL)OXY)METHYL KETONES AS INTERLEUKIN-1-BETA CONVERTING-ENZYME INHIBITORS - SIGNIFICANCE OF THE P-1 AND P-3 AMIDO NITROGENS FOR ENZYME-PEPTIDE INHIBITOR BINDING [J].
DOLLE, RE ;
SINGH, J ;
RINKER, J ;
HOYER, D ;
PRASAD, CVC ;
GRAYBILL, TL ;
SALVINO, JM ;
HELASZEK, CT ;
MILLER, RE ;
ATOR, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (23) :3863-3866
[10]   EFFICIENT TOTAL SYNTHESIS OF DIDEMNINS A AND B [J].
HAMADA, Y ;
KONDO, Y ;
SHIBATA, M ;
SHIOIRI, T .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (02) :669-673